The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma
Shigeo Shimose(Kurume University), Takumi Kawaguchi(Kurume University), Masahito Nakano(Kurume University), Hideko Ohama(Osaka Medical and Pharmaceutical University), Hironori Koga(Kurume University), Takuji Torimura(Omuta hospital), Naoki Kamachi(Kurume University), Dan Nakano(Kurume University), Margherita Rimini(Vita-Salute San Raffaele University), Tsubasa Tsutsumi(Kurume University), Atsushi Hiraoka(Ehime Prefectural Central Hospital), Etsuko Moriyama(Kurume University), Valentina Burgio(Vita-Salute San Raffaele University), Hideya Suga(Yanagawa Rehabilitation Hospital), Masatoshi Tanaka(Fukushima Medical University), Fujimasa Tada(Ehime Prefectural Central Hospital), Hideki Iwamoto, Ryoko Kuromatsu(Kurume University), Andrea Casadei‐Gardini(Vita-Salute San Raffaele University), Takashi Niizeki(Kurume University), Yu Noda(Kurume University), Hiroyuki Suzuki(Kurume University), Tomotake Shirono(Kurume University)
Cited by 31
Related Papers
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3
|American Journal Of Pathology|2004|536
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
|Journal of Hepatology|2016|504